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Abstract
TOX3 maps to 16q12, a region commonly lost in breast cancers and recently implicated in the risk of developing breast
cancer. However, not much is known of the role of TOX3 itself in breast cancer biology. This is the first study to determine
the importance of TOX3 mutations in breast cancers. We screened TOX3 for mutations in 133 breast tumours and identified
four mutations (three missense, one in-frame deletion of 30 base pairs) in six primary tumours, corresponding to an overall
mutation frequency of 4.5%. One potentially deleterious missense mutation in exon 3 (Leu129Phe) was identified in one
tumour (genomic DNA and cDNA). Whilst copy number changes of 16q12 are common in breast cancer, our data show that
mutations of TOX3 are present at low frequency in tumours. Our results support that TOX3 should be further investigated to
elucidate its role in breast cancer biology.
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Introduction
We recently performed a genome wide association study using
single nucleotide polymorphism (SNP) tagged haplotypes, in which
rs3803662 was associated with breast cancer risk [1]. This was the
second strongest association identified in this study. rs3803662 tags
for a linkage disequilibrium block spanning the 59 regulatory
sequences of the gene TOX3 (TOX high mobility group box family
member 3) and the 39 region of the neighbouring hypothetical gene
LOC643714. A second genome wide association study [2]
identified a significant association between the T allele of
rs380662 and the development of oestrogen receptor (ER) positive
breast cancer. However, neither TOX3 nor LOC643714 has been
established as the risk gene inside this interval. More recently, the
16q12 risk locus has been reported to modulate the affinity of
FOXA1 binding to chromatin, possibly regulating TOX3 expres-
sion [3].
TOX3 is located in chromosome 16q12 and consists of seven
exons. Although it is predominantly expressed in brain, it is also
expressed in breast, with breast tumours expressing it at a higher
level than in normal tissue [4,5]. The protein encoded by TOX3
contains a high mobility group box (HMG-box) and a glutamine-
rich C-terminus (consisting of CAG repeats). It has calcium-
dependent transcriptional activity and is a co-factor of CREB and
CBP [4,6,7].
Loss of heterozygosity (LOH) of the 16q region is commonly
observed in breast cancers (33.9% primary tumours), including a
2.3% frequency of homozygous deletions [8]. Several breast
cancer cell lines also present chromosomal translocations centro-
meric to this region [8]. Nevertheless, an important tumour-
suppressor gene in this region remains to be identified.
Although TOX3 falls out of the minimum LOH region, in view
of the highly significant association of rs3803662 with breast
cancer risk, we hypothesised TOX3 to be a likely candidate
tumour-suppressor gene present on the 16q arm. In the present
study we selected 2 sets of primary breast tumours and screened
TOX3 for mutations in the entire coding region, to ascertain
whether TOX3 mutations have a role in breast cancer.
Materials and Methods
Ethics Statement
Written informed consent was obtained from all subjects for the
collection and research use of breast tumours. Control samples
were purified from anonymous waste products of blood donations
(leukocyte reduction fliters), and did not require written consent.
Both collections were approved by the Addenbrooke’s Hospital
Local Research Ethics Committee (REC reference 07/H0308/
161 and 04/Q0108/21, breast tumours and blood respectively)
and the Nottingham Tenovus Primary Breast Cancer Series.
Cases and Controls
Patients were recruited from two hospitals: 42 samples were
collected from Addenbrookes Hospital and another 96 samples
were part of a previously described cohort from Nottingham
Hospital [8] (Table S1 – Demographics of sample sets).
Lymphocytes of 136 healthy fresh blood donors were used as
controls. These samples were collected from anonymous white
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cell-reduction filters from blood donations were collected from the
Blood Centre at Addenbrooke’s Hospital, and lymphocytes were
separated by density gradient and magnetic sorting, as previously
described [9].
Nucleic Acid Isolation
DNA from tumours was extracted from 20 sections of 30 mm
using the Promega DNA Wizard kit (Promega) according to
manufacturer’s instructions. Lymphocyte DNA was extracted by a
conventional SDS/proteinase K/phenol method. All DNA
samples were quantified with a NanoDrop ND-1000 spectropho-
tometer (NanoDrop Technologies). Genomic DNA from primary
tumours was whole-genome amplified (WGA) using the REPLI-g
kit from QIAGEN, according to the manufacturer’s instructions.
Total RNA was extracted from all samples using Qiazol
(Invitrogen) following manufacturer’s instructions. The RNA was
subsequently treated with DNaseI. cDNA was prepared from 1 mg
of total RNA per 20 ml reaction using random hexamers and the
Reverse Transcription kit (Applied Biosystems), according to the
manufacturer’s instructions, and was diluted in a final volume of
100 ml.
Mutation Analysis
Whole-genome amplified DNA from primary tumours and
genomic DNA from control blood samples were amplified for all
seven exons by PCR using primers designed with Primer3 software
(sequences provided as File S1). PCR amplification of genomic
DNA was carried out for all seven exons in 20 ml reaction
containing 10 pmol of each primer, 200 mM of each dNTP
(Promega), 1.5 mM MgCl2, 16AmpliTaq Gold buffer II (Applied
Biosystems) and 0.1 units of AmpliTaq Gold polymerase (Applied
Biosystems). Cycling conditions were 95uC for 5 min, followed by
35–40 cycles consisting of 30 seconds at 95uC, 30 seconds at 56uC
and 1 min at 72uC, finishing with a final extension step of 5 min at
72uC. The annealing temperature was 56uC for all exons except
for exon1 amplification (58uC), and PCRs for exons 1, 2 and 5
required the addition of the CES additive [10]. cDNA was
amplified for all samples with mutations using the KAPA2G
Robust PCR kit (KapaBiosystems), following the manufacturer’s
instructions. Cycling conditions were 95uC for 3 min, followed by
35 cycles consisting of 15 seconds at 95uC, 15 seconds at 60uC and
15 seconds at 72uC, finishing with a final extension step of 5 min
at 72uC. PCR products were purified using either the QIAquick
kit (QIAGEN) or using NucleoFast 96-well plates (Macherey-
Nagel), and eluted in a final volume of 30 ml.
Sequencing was performed using BigDye Terminator Cycle
Sequencing Ready Reaction solution (Applied Biosystems). All
products were sequenced in both directions except for exon 7A,
which was sequenced only in the forward direction, and therefore
repeated twice. All mutations were validated with re-amplification
and sequencing of non-WGA tumour DNA and cDNA. The
sequencing data was analyzed using DNAStar Lasergene8.0
SeqMan software and compared to the sequences deposited on
ENSEMBL (genomic sequence ENSG00000103460, cDNA
ENST00000219746 and ENST00000407228). All variants iden-
tified in this study were verified in the dbSNP database and the
1000 Genomes Project data.
Expression Analysis
Expression data for these samples already existed performed on
an Agilent platform as reported previously [11].
Relative allelic expression ratios were determined during the
sequencing of cDNA samples, by measuring the area under the
peaks in the chromatograms for the mutant vs the wild-type bases.
In-silico Analysis
Candidate deleterious mutations were investigated for putative
splice variants, protein structure and function alterations using the
Human Splicing Finder, the PSIPRED Protein Structure Predic-
tion Server and SIFT Sorting Intolerant from Tolerant web-based
software [12–14]. All in-silico data is provided as Files S2 and S3.
Results
We screened all seven exons of TOX3 for mutations in one set of
46 primary tumour samples using Sanger sequencing. The screen
of the second set of 96 samples was focused on exons two to seven
for which variants were identified in the first set. In total, we
acquired good quality data for 133 tumours. Table 1 provides a
Table 1. Mutations in TOX3 in primary breast tumours.
Mutation Tumour
Nucleotide
and aminoacid Exon Codon Type
Effect
Predictiona Frequency Typeb
ER
Status Metastasis
16q12
LOH
CDH1
Mutation
Allelic
Expressionc #
c.190T.C 3 64 Missense Positive 1/124 Luminal A Pos No No No WT 1
(p.Phe64Leu)
c.385C.T 3 129 Missense Positive 1/124 Luminal A Pos No No No MUT.WT 2
(p.Leu129Phe)
Normal Pos No No No WT 3
c.1304C.Td 7 435 Missense Negative 3/133 – – No – No MUT=WT 4
(p.Ser435Leu) Luminal A Pos No Yes No MUT 5
c.1525_1554del 7 509–518 Deletion Positive 1/133 Luminal A Pos Yes Yes Gln23* WT 6
(p.Gln509_Gln518del)
aIn-silico prediction (data shown as Files S2 and S3).
bPAM50 classification [15,16].
cWT, only the wild-type allele is detected in the tumour mRNA; MUT, only the mutated allele is detected in the tumour mRNA; MUT =WT and MUT.WT, both mutated
and wild-type alleles are detected in the tumour mRNA in equimolar amounts or the mutated allele in higher quantity.
dReported in COSMIC [20].
doi:10.1371/journal.pone.0074102.t001
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summary of all identified mutations. The mutation frequency
displayed in Table 1 corresponds to the total number of samples
for which a successful PCR product was obtained and sequenced
for each exon.
We found four different mutations in exons three and seven in a
total of six tumours: three missense mutations and one deletion
(Figure 1).
Figure 1. TOX3 mutations in primary breast tumours. A) Direct sequencing profiles of genomic and complementary DNA are shown for all
mutations. Arrows indicate the site of the nucleotide change associated with each mutation. B) Overview of the TOX3 mutations identified in breast
cancer. Genomic localisation of TOX3, relative position to the susceptibility associated SNP rs3803662 (shown in green) and scheme of the protein
encoded by TOX3 with the site of the identified mutations (not to scale). The HMG-box domain is shown in orange.
doi:10.1371/journal.pone.0074102.g001
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One tumour sample presented a missense mutation, c.190T.C
(Figure 1), leading to a p.Phe64Leu alteration in the protein
sequence. This is not predicted to change the folding of TOX3
(PSIPRED) but has a predicted damaging effect according to
SIFT. Analysis of the cDNA of the same sample revealed that the
mutated allele is not expressed, which suggests that this is a non-
deleterious mutation. This tumour is a ER positive Luminal A type
tumour.
Another missense mutation was identified in another ER
positive Luminal A type tumour, c.385C.T, leading to a leucine
to phenylalanine substitution at codon 129 (p.Leu129Phe). This
change is not predicted to change the folding of TOX3 according
to PSIPRED, but is predicted to have a damaging effect on the
protein structure and function according to SIFT. Sequencing of
the cDNA of this tumour revealed that the mutated allele is
preferentially expressed in the tumour [60% mutant : 40% wild-
type], when compared with the allelic proportion of mutant by
wild-type in the genomic DNA (Figure1 A). This is potentially a
deleterious mutation that warrants further investigation.
A missense mutation in exon seven was detected in three
samples, c.1304C.T, resulting in a serine to leucine modification
at codon 435 (p.Ser435Leu). According to the in-silico analysis,
this mutation is not predicted to modify the folding or function of
the TOX3 protein (PSIPRED and SIFT), but interestingly it is
differentially expressed between the tumours. A ‘‘Normal-like’’
type ER positive tumour with neutral copy number in this region
only expresses the wild-type allele. Another tumour, Luminal A
type ER positive, with LOH in 16q12 (tumour 7, Figure 1A)
expresses exclusively the mutated allele. This indicates that both
alleles of TOX3 are potentially inactivated in this tumour, one by
LOH and the other by point mutation. A third tumour without
CGH data available expresses equimolar proportions of mutant
and wild-type alleles.
Finally, an in-frame deletion of 30 bp inside exon 7,
c.1525_1554del, was detected in one sample with LOH in
16q12 (Figure 1), resulting in the loss of 10 amino acids. This
tumour only presented the expression of the wild-type full-length
allele, which suggests that this is a non-deleterious mutation. This
tumour is o type Luminal A type, ER positive and presented
metastasis (not to the bone). This is as well the only tumour for
which CDH1 is mutated (Gln23* nonsense mutation).
The small number of samples with mutations does not permit
statistical analysis correlating mutations and clinical characteristics
of the tumours. Nevertheless, besides one tumour for which we
have very limited information and another which is ‘‘normal-like’’,
all tumours carrying mutations were of the Luminal A type, and
are all ER positive [15,16]. Additionally, two patients presented
with metastasis.
To investigate whether the mutational status of these tumours
was associated with altered levels of expression of TOX3, we
compared mutated vs non-mutated.
Discussion
To our knowledge this is the first mutation screen of TOX3 in
breast cancer. Our rationale for performing this screen was that
TOX3 maps to a known breast cancer susceptibility locus, which is
also commonly a region of LOH in breast cancer. We
hypothesised that TOX3 could be a candidate tumour suppressor
gene in 16q.
In our study, we found a frequency of 4.5% coding TOX3
mutations in primary breast tumours, clustered in exon 3 and in
exon 7 (the latter contains the trinucleotide repeat region)
(Figure 1B). In-silico predictions indicated that three of the coding
mutations have a potential deleterious effect on protein secondary
structure or function. Of these, one is expressed by the tumour and
therefore potentially pathogenic (p.Leu129Phe, exon 3). The other
two are not expressed by the corresponding tumours, and
therefore are unlikely to be disease-causing. The variability of
preferential expression of the mutant vs wild-type allele in the
samples without LOH can be an indication of differential allelic
methylation within the tumours, which can lead to loss of
expression from one allele. However, all mutations detected in
our samples were outside of the HMG-box region (Figure 1B),
suggesting that the DNA binding ability of the mutant proteins
should not be affected.
The only tumour suppressor gene identified to date in this LOH
region in breast tumours is CDH1 (E-cadherin). Mutations in CDH1
are associated with lobular tumours and have been reported at a
frequency of 6.7% [17]. Only one of our samples was also mutated
in this gene (Tumour 6, a nonsense mutation). Also, we found that
four out of five tumours with TOX3 mutations, for which we had
clinical information, were of Luminal A type. This result suggests
that mutations in these two genes might be associated with
different sub-types of breast tumours.
The function these mutations might be altering or exerting still
remains unclear. Recent reports have provided data that both
support and reject the tumour suppressor role of TOX3. Two
studies have reported an association of the risk allele of rs3803662
and lower expression of TOX3 in an allele-specific manner [3,18].
One of these studies also links the lower expression of TOX3 with
tumour grade and poorer outcome [18]. Interestingly, this study
reports a stronger effect of the risk allele of rs3803662 in Luminal
A tumours, the same sub-type in which we detect mutations in our
study. In our own set, it is unlikely that the mutations are altering
the expression of TOX3, as we did not find significant expression
differences between mutated vs non-mutated samples (Figure S1).
On the other hand, an association between TOX3 overexpression
in tumours and lower BRCA1 expression and tumour aggressiveness
has been reported recently [19]. Nevertheless, this study also
reports genomic amplification of TOX3 in advanced breast
tumours, which we did not detect in our own samples. It is possible
that TOX3 might play a complex role in promoting tumour
development or protecting against it in a subtype-specific manner.
It has also been shown that the effects of TOX3 expression and
of the risk allele of rs3803662 in breast cancer is stronger in ER
positive tumours [1,4,18]. Interestingly, all the samples in which
we detected mutations are also ER-positive. Thus, our data further
supports the link between TOX3 and oestrogen-dependent
transcription.
In conclusion, our study reveals that TOX3 is mutated in breast
tumours, albeit at a low frequency. Of the four mutations
identified in this study, three are expressed in the tumours and
one is potentially deleterious. These results add to the evidence
that TOX3 is associated with breast cancer, but require validation
in a larger set to clarify the role of these mutations in tumour
development and progression.
Supporting Information
Figure S1 Expression of TOX3 in sample with and without
mutations.
(EPS)
Table S1 Demographics of samples sets.
(DOC)
File S1 Oligonucleotide sequences.
(TIFF)
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File S2 SIFT Prediction Results, for the missense mutations
based on the sequences of the two TOX3 variants
(ENSP00000385705, ENSP00000219746).
(TIFF)
File S3 PSIPRED Prediction Results, for the missense and
deletion mutations.
(TIFF)
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